Tech Company Financing Transactions

Vivacta Biotechnology Funding Round

On 4/29/2026, Vivacta Biotechnology raised $50 million in Series A funding from Decheng Capital, Loyal Valley Capital and C&D Emerging Investment.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

1-5 Floor, Building 24, 388 Shengrong Road, Pudong New Area
Shanghai, 200120
China

Phone

(86) 021-50828029

Website

www.vivacta-bio.com

Email Address

[email protected]

Overview

Vivacta Bio is a biotechnology company dedicated to developing next-generation in vivo CAR-T therapies for cancer and autoimmune diseases. Leveraging innovations in T-cell--targeted LNP design and advanced mRNA engineering, Vivacta Bio aims to transform complex cell-manufacturing workflows into a convenient, scalable, and repeat-dose in vivo treatment paradigm, broadening global access to transformative immunotherapies. Vivacta Bio is headquartered in Shanghai, China.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Liu Yarong

        

Browse more venture capital transactions:

Prev: 4/29/2026: Dex Talent venture capital transaction
Next: 4/29/2026: Firestorm Labs venture capital transaction

Share this article

About Our VC Transactions Data

Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary